ReviewFrontiers in immunology2026
Optimizing immunotherapy in advanced gastric cancer: established and emerging biomarkers for precision patient selection.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
mmune checkpoint inhibitors have reshaped the therapeutic landscape of advanced gastric and gastroesophageal junction cancer, yet durable benefit remains restricted to biologically selected patient subgroups. Optimizing immunotherapy, therefore, requires a disease-specific, clinically practical, and critically interpreted biomarker framework rather than reliance on any single predictive marker. This review synthesizes established and emerging biomarkers for immune checkpoint inhibitor selection in advanced, metastatic, and perioperative gastric cancer, with emphasis on programmed death-ligand 1 combined positive score, deficient mismatch repair/microsatellite instability-high status, tumor mutational burden, Epstein-Barr virus-associated tumors, HER2-defined combination strategies, tumor microenvironment features, circulating tumor DNA dynamics, and artificial intelligence-assisted models. In addition to summarizing biological rationale, this review critically evaluates trial-based limitations that influence biomarker interpretation, including assay variability, spatial and temporal heterogeneity, dynamic PD-L1 expression, inconsistent CPS thresholds, overlap between TMB-high and MSI-H biology, and the limited prospective validation of exploratory markers. Recent perioperative and neoadjuvant ICI studies are discussed to highlight how early biomarker testing may guide treatment intensification, de-escalation, or trial selection in resectable disease. Emerging evidence supporting TMEscore, longitudinal ctDNA response, and multimodal AI-based prediction is also examined, with an emphasis on the current barriers to routine clinical implementation. Finally, this review proposes a tiered, resource-aware interpretation of biomarkers that distinguishes clinically actionable markers from investigational tools and addresses challenges related to standardization, cost, access, and equity. Overall, biomarker-guided integration of molecular, immune, dynamic, and translational markers is essential to improve patient selection and advance precision immunotherapy in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.